Relationship between galectin-3 LEVELS and MINERALOCORTICOID RECEPTOR ANTAGONIST USE in HEART FAILURE: Analysis from HF-ACTION

Journal of Cardiac Failure

Volumn 20, Issue 1, 2014, Pages 38-44

  Fiuzat, Mona ^a,b   Schulte, Phillip J ^b   Felker, Michael ^a,b   Ahmad, Tariq ^a,b   Neely, Megan ^b   Adams, Kirkwood F ^e   Donahue, Mark P ^a   Kraus, William E ^a   Piña, Ileana L ^d   Whellan, David J ^c   O'Connor, Christopher M ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

biomarkers; galectin 3; Heart failure; mineralocorticoid receptor antagonists

Indexed keywords

GALECTIN 3; MINERALOCORTICOID ANTAGONIST;

ADULT; AGED; ARTICLE; EXERCISE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL;

BIOMARKERS; GALECTIN-3; HEART FAILURE; MINERALOCORTICOID RECEPTOR ANTAGONISTS;

BIOLOGICAL MARKERS; CHRONIC DISEASE; EXERCISE THERAPY; FEMALE; GALECTIN 3; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MORTALITY; OUTPATIENTS; PROGNOSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84892642395     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2013.11.011     Document Type: Article

References (33)

1. R.A. de Boer, A.A. Voors, P. Muntendam, W.H. van Gilst, and D.J. van Veldhuisen Galectin-3: A novel mediator of heart failure development and progression Eur J Heart Fail 11 2009 811 817
2. G.M. Felker, M. Fiuzat, L.K. Shaw, R. Clare, D.J. Whellan, and L. Bettari et al. Galectin-3 in ambulatory patients with heart failure: Results from the hf-action study Circ Heart Fail 5 2012 72 78
3. L. Gullestad, T. Ueland, J. Kjekshus, S.H. Nymo, J. Hulthe, and P. Muntendam et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) Am Heart J 164 2012 878 883
4. J.E. Ho, C. Liu, A. Lyass, P. Courchesne, M.J. Pencina, and R.S. Vasan et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community J Am Coll Cardiol 60 2012 1249 1256
5. M. Hayashi, T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, and T. Tsutsui et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction J Am Coll Cardiol 38 2001 1375 1382 (Pubitemid 33033014)
6. L. Calvier, M. Miana, P. Reboul, V. Cachofeiro, E. Martinez-Martinez, and R.A. de Boer et al. Galectin-3 mediates aldosterone-induced vascular fibrosis Arterioscler Thromb Vasc Biol 33 2013 67 75
7. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, and B. Roniker et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure E, Survival Study I. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321 (Pubitemid 36384098)
8. A.F. Hernandez, X. Mi, B.G. Hammill, S.C. Hammill, P.A. Heidenreich, and F.A. Masoudi et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction JAMA 308 2012 2097 2107
9. T. Ahmad, and G.M. Felker Galectin-3 in heart failure: more answers or more questions? J Am Heart Assoc 1 2012 e004374
10. R.V. Shah, A.A. Chen-Tournoux, M.H. Picard, R.R. van Kimmenade, and J.L. Januzzi Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure Eur J Heart Fail 12 2010 826 832
11. T. Ahmad, and C.M. O'Connor Therapeutic implications of biomarkers in chronic heart failure Clin Pharmacol Ther 94 2013 468 479
12. F. Azibani, L. Benard, S. Schlossarek, R. Merval, F. Tournoux, and L. Fazal et al. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart Hypertension 59 2012 1179 1187
13. R.A. Weir, C.J. Petrie, C.A. Murphy, S. Clements, T. Steedman, and A.M. Miller et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction Circ Heart Fail 6 2013 492 498
14. L. Gullestad, T. Ueland, J. Kjekshus, S.H. Nymo, J. Hulthe, and P. Muntendam et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) Eur Heart J 33 2012 2290 2296
15. C.M. O'Connor, D.J. Whellan, K.L. Lee, S.J. Keteyian, L.S. Cooper, and S.J. Ellis et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial JAMA 301 2009 1439 1450
16. S.A. Hunt, W.T. Abraham, M.H. Chin, A.M. Feldman, G.S. Francis, and T.G. Ganiats et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 2009 e391 e479
17. M. Jessup, W.T. Abraham, D.E. Casey, A.M. Feldman, G.S. Francis, and T.G. Ganiats et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation Circulation 119 2009 1977 2016
18. C.M. O'Connor, D.J. Whellan, D. Wojdyla, E. Leifer, R.M. Clare, and S.J. Ellis et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model Circ Heart Fail 5 2012 63 71
19. P.C. Austin Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples Stat Med 28 2009 3083 3107
20. U.C. Sharma, S. Pokharel, T.J. van Brakel, J.H. van Berlo, J.P. Cleutjens, and B. Schroen et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 2004 3121 3128 (Pubitemid 39492008)
21. T. Ueland, P. Aukrust, K. Broch, S. Aakhus, R. Skardal, P. Muntendam, and L. Gullestad Galectin-3 in heart failure: high levels are associated with all-cause mortality In J Cardiol 150 2011 361 364
22. R.A. de Boer, D.J. Lok, T. Jaarsma, P. van der Meer, A.A. Voors, and H.L. Hillege et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 2011 60 68
23. D.J. Lok, P. van der Meer, P.W. de la Porte, E. Lipsic, J. van Wijngaarden, and H.L. Hillege et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study Clin Res Cardiol 99 2010 323 328
24. R.A. Weir, C.J. Petrie, C.A. Murphy, S. Clements, T. Steedman, and A.M. Miller et al. Response to letter regarding article, "Galectin-3 and Cardiac Function in Survivors of Acute Myocardial Infarction." Circ Heart Fail 6 2013 e58
25. I.S. Anand, T.S. Rector, M. Kuskowski, A. Adourian, P. Muntendam, and J.N. Cohn Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the VAL-HEFT Eur J Heart Fail 15 2013 511 518
26. F. Zannad, J.J. McMurray, H. Krum, D.J. van Veldhuisen, K. Swedberg, and H. Shi et al. Group E-HS. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
27. B. Pitt, F. Zannad, W.J. Remme, R. Cody, A. Castaigne, and A. Perez et al. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717 (Pubitemid 29407370)
28. N.M. Albert, C.W. Yancy, L. Liang, X. Zhao, A.F. Hernandez, and E.D. Peterson et al. Use of aldosterone antagonists in heart failure JAMA 302 2009 1658 1665
29. C.G. Brilla, L.S. Matsubara, and K.T. Weber Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension Am J Cardiol 71 1993 12A 16A (Pubitemid 23046406)
30. G.C. Fonarow, N.M. Albert, A.B. Curtis, M. Gheorghiade, Y. Liu, and M.R. Mehra et al. Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case-control analysis of IMPROVE HF J Am Heart Assoc 1 2012 16 26
31. S. Hamaguchi, S. Kinugawa, M. Tsuchihashi-Makaya, K. Goto, D. Goto, and T. Yokota et al. Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure Am Heart J 160 2010 1156 1162
32. L.H. Cavallari, V.L. Groo, K.M. Momary, D. Fontana, M.A. Viana, and P. Vaitkus Racial differences in potassium response to spironolactone in heart failure Congest Heart Fail 12 2006 200 205
33. N.D. Fisher, R.E. Gleason, T.J. Moore, G.H. Williams, and N.K. Hollenberg Regulation of aldosterone secretion in hypertensive blacks Hypertension 23 1994 179 184 (Pubitemid 24050278)